However, we cannot exclude an action of denosumab on breast cancer cells themselves, which have previously been shown to express high receptor activator of nuclear factor κB (RANK) levels [13, 14] and may be susceptible to its inhibition. This evidence concerns the gene TNFRSF11A and breast cancer.